186Re-HEDP: a potential therapeutic bone agent.
A lyophilized kit preparation of HEDP for labelling with 186Re has been developed as a potential bone agent useful for both diagnosis and therapy. High pressure liquid chromatographic analysis showed that the 186Re-HEDP is a mixture of several components. Preliminary in vivo studies in several animal species showed that both the 186Re-HEDP mixture and the HPLC-purified main component are bone-seeking agents with slow blood and soft-tissue clearance rates. HPLC purification slightly improved the quality of the image. In mice and rats with trauma-induced osteogenetic activity in one leg, the bone uptake of the traumatized leg was 1.7-1.9 times higher than of the normal leg. The lesion-to-normal bone ratio was 4-5.4.
D000818:Animals; D001859:Bone Neoplasms / Q000532:radiotherapy / Q000556:secondary; D001842:Bone and Bones / Q000000981:diagnostic imaging*; D004285:Dogs; D012968:Etidronic Acid; D051379:Mice; D011868:Radioisotopes / Q000627:therapeutic use; D011877:Radionuclide Imaging; D051381:Rats; D012211:Rhenium / Q000627:therapeutic use
D011868:Radioisotopes; D012211:Rhenium; D012968:Etidronic Acid